Citi analyst David Lebowitz initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Neutral rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage

Viking Therapeutic (VKTX) PT Lowered to $70 at Maxim GroupFebruary 6, 2025 12:11 PM Viking Therapeutic (VKTX) PT Lowered to $95 at Truist SecuritiesFebruary 6, 2025 12:07 PM Viking Therapeutic (VKTX) PT Lowered to $71 at Piper SandlerFebruary 6, 2025 7:06 AM H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)February 6, 2025 6:41 AM Viking Therapeutics (VKTX) Misses Q4 EPS by 4cFebruary 5, 2025 4:13 PM Form 8-K Viking Therapeutics, For: Feb 05February 5, 2025 4:08 PM Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate UpdateFebruary 5, 2025 4:05 PM Viking Therapeutics (VKTX) call put ratio 16 calls to 1 put with a focus on February 7 weekly calls into quarter resultsFebruary 5, 2025 10:46 AM